You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers
|
|---|---|
| Published in |
Clinical Epigenetics, June 2016
|
| DOI | 10.1186/s13148-016-0237-y |
| Pubmed ID | |
| Authors |
Jeannine Diesch, Anabel Zwick, Anne-Kathrin Garz, Anna Palau, Marcus Buschbeck, Katharina S. Götze |
| Abstract |
The azanucleosides azacitidine and decitabine are currently used for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in patients not only eligible for intensive chemotherapy but are also being explored in other hematologic and solid cancers. Based on their capacity to interfere with the DNA methylation machinery, these drugs are also referred to as hypomethylating agents (HMAs). As DNA methylation contributes to epigenetic regulation, azanucleosides are further considered to be among the first true "epigenetic drugs" that have reached clinical application. However, intriguing new evidence suggests that DNA hypomethylation is not the only mechanism of action for these drugs. This review summarizes the experience from more than 10 years of clinical practice with azanucleosides and discusses their molecular actions, including several not related to DNA methylation. A particular focus is placed on possible causes of primary and acquired resistances to azanucleoside treatment. We highlight current limitations for the success and durability of azanucleoside-based therapy and illustrate that a better understanding of the molecular determinants of drug response holds great potential to overcome resistance. |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 2 | 29% |
| United Kingdom | 2 | 29% |
| United States | 1 | 14% |
| Unknown | 2 | 29% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 57% |
| Scientists | 3 | 43% |
Mendeley readers
The data shown below were compiled from readership statistics for 198 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 198 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 38 | 19% |
| Student > Ph. D. Student | 32 | 16% |
| Student > Master | 27 | 14% |
| Researcher | 22 | 11% |
| Student > Doctoral Student | 10 | 5% |
| Other | 20 | 10% |
| Unknown | 49 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 63 | 32% |
| Medicine and Dentistry | 31 | 16% |
| Agricultural and Biological Sciences | 21 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 4% |
| Chemistry | 6 | 3% |
| Other | 14 | 7% |
| Unknown | 56 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 December 2021.
All research outputs
#2,314,014
of 22,653,392 outputs
Outputs from Clinical Epigenetics
#133
of 1,231 outputs
Outputs of similar age
#44,248
of 352,649 outputs
Outputs of similar age from Clinical Epigenetics
#5
of 26 outputs
Altmetric has tracked 22,653,392 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,231 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 352,649 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.